The FDA has granted orphan drug status for the treatment for patients with Rett syndrome to BHV-5000, an investigational compound in the glutamate modulation platform of Biohaven Pharmaceutical Holding Company.

This is the company’s fourth product candidate to receive orphan drug designation from the FDA.

“BHV-5000 is a novel glutamate antagonist that Biohaven plans to evaluate for efficacy across several therapeutic indications,” said Vlad Coric, M.D., CEO of Biohaven.